Related references
Note: Only part of the references are listed.Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Caterina Marchio et al.
SEMINARS IN CANCER BIOLOGY (2021)
New Advances in Molecular Breast Cancer Pathology
Emad A. Rakha et al.
SEMINARS IN CANCER BIOLOGY (2021)
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer
Hsing-Ju Wu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Quantitative Whole Slide Assessment of Tumor-Infiltrating CD8-Positive Lymphocytes in ER-Positive Breast Cancer in Relation to Clinical Outcome
Danielle Krijgsman et al.
IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS (2021)
The Exciting New Field of HER2-Low Breast Cancer Treatment
Daniel Eiger et al.
CANCERS (2021)
Machine-Learning-Based Evaluation of Intratumoral Heterogeneity and Tumor-Stroma Interface for Clinical Guidance
Arvydas Laurinavicius et al.
AMERICAN JOURNAL OF PATHOLOGY (2021)
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha et al.
BRITISH JOURNAL OF CANCER (2021)
Artificial Intelligence & Tissue Biomarkers: Advantages, Risks and Perspectives for Pathology
Cesare Lancellotti et al.
CELLS (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups
Ji Won Woo et al.
HUMAN PATHOLOGY (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunogradient Indicators for Antitumor Response Assessment by Automated Tumor-Stroma Interface Zone Detection
Allan Rasmusson et al.
AMERICAN JOURNAL OF PATHOLOGY (2020)
Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer
Rashmi Verma et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Maria Vittoria Dieci et al.
CANCER TREATMENT REVIEWS (2020)
Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers
M. Angeles Lopez-Garcia et al.
CANCERS (2020)
Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
Dovile Zilenaite et al.
FRONTIERS IN ONCOLOGY (2020)
Integration of Online Omics-Data Resources for Cancer Research
Tonmoy Das et al.
FRONTIERS IN GENETICS (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
James Crespo et al.
PLOS ONE (2020)
The neoepitope landscape of breast cancer: implications for immunotherapy
Pooja Narang et al.
BMC CANCER (2019)
Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
Zhi-Hua Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S. Kim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
Gaia Griguolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update
Adlin M. Gordian-Arroyo et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer
Bin Xu et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab
Marco Invernizzi et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
Marcelo Sobral-Leite et al.
BREAST CANCER RESEARCH (2019)
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER plus Breast Cancer
Andreas Heindl et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER plus Breast Cancer
Andreas Heindl et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?
Yiwei Tong et al.
EUROPEAN JOURNAL OF CANCER (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Hiroji Iwata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer
Morten Ragn Jakobsen et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
P. Nuciforo et al.
ANNALS OF ONCOLOGY (2018)
'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study
Morgan Ballard et al.
MODERN PATHOLOGY (2017)
Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue
Gedmante Radziuviene et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Mirjana Efremova et al.
FRONTIERS IN IMMUNOLOGY (2017)
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
Sotirios P. Fortis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Direct estrogen receptor (ER)/HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER plus breast cancer
Denis Collins et al.
PLOS ONE (2017)
HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
Yanjun Hou et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials
C. Solinas et al.
CANCER TREATMENT REVIEWS (2017)
HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
Yanjun Hou et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2017)
Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry
Henrik O. Helin et al.
VIRCHOWS ARCHIV (2016)
The genomic landscape of breast cancer and its interaction with host immunity
Stephen Luen et al.
BREAST (2016)
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2016)
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
Maria Vittoria Dieci et al.
CANCER TREATMENT REVIEWS (2016)
Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge
Tiziana Triulzi et al.
FUTURE ONCOLOGY (2016)
Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma
Arvydas Laurinavicius et al.
VIRCHOWS ARCHIV (2016)
Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis
Rachael Natrajan et al.
PLOS MEDICINE (2016)
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
Edith A. Perez et al.
JAMA ONCOLOGY (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
Yan Mao et al.
PLOS ONE (2016)
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers
Giulia Bottai et al.
BREAST CANCER RESEARCH (2016)
Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
Hee Jin Lee et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Optimizing HER2 assessment in breast cancer: application of automated image analysis
Henrik Holten-Rossing et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
A leave-one-out cross-validation SAS macro for the identification of markers associated with survival
Christel Rushing et al.
COMPUTERS IN BIOLOGY AND MEDICINE (2015)
Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization
Gillian C. Bethune et al.
HISTOPATHOLOGY (2015)
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer
Sidra Nawaz et al.
MODERN PATHOLOGY (2015)
A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data
Benoit Plancoulaine et al.
VIRCHOWS ARCHIV (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer
Yinyin Yuan
JOURNAL OF THE ROYAL SOCIETY INTERFACE (2015)
An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer
Carlo C. Maley et al.
BREAST CANCER RESEARCH (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
Wedad M. Hanna et al.
MODERN PATHOLOGY (2014)
The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini et al.
LANCET ONCOLOGY (2014)
Gene Status in HER2 Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based Method
Anna Sapino et al.
ONCOLOGIST (2014)
Intratumoral CD8+ Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer
Zonglin Chen et al.
PLOS ONE (2014)
Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity
Vanessa Almendro et al.
CELL REPORTS (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
Ariadna Tibau et al.
NEOPLASIA (2014)
A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative
O. Brouckaert et al.
ANNALS OF ONCOLOGY (2013)
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
F. Montemurro et al.
ANNALS OF ONCOLOGY (2013)
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
Mario Giuliano et al.
BREAST CARE (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains
Anja Brugmann et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
Qingfei Wang et al.
CANCER RESEARCH (2012)
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Hyesil Seol et al.
MODERN PATHOLOGY (2012)
Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue
Steven J. Potts et al.
LABORATORY INVESTIGATION (2012)
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies et al.
PLOS ONE (2012)
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Isabel Pinhel et al.
BREAST CANCER RESEARCH (2012)
CD8(+) lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2012)
Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays
Aida Laurinaviciene et al.
DIAGNOSTIC PATHOLOGY (2011)
Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade
Kristi Baker et al.
HISTOPATHOLOGY (2011)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
HER2 genetic heterogeneity in breast carcinoma
Christian Oehlschlegel et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
Kathleen A. Cronin et al.
CANCER INVESTIGATION (2010)
Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation
Lynne Dobson et al.
HISTOPATHOLOGY (2010)
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype
So Yeon Park et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
John M. S. Bartlett et al.
LANCET ONCOLOGY (2010)
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
Monica M. Reinholz et al.
LANCET ONCOLOGY (2009)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
Grazia Arpino et al.
ENDOCRINE REVIEWS (2008)
Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer
Ivar Skaland et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2008)
Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities
Suleiman Massarweh et al.
CLINICAL CANCER RESEARCH (2007)
DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage
MC Zody et al.
NATURE (2006)
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
R Clarke et al.
ONCOGENE (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
